StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

Kiniksa Pharmaceuticals International price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Kiniksa Pharmaceuticals International's price to book ratio was 12.0× on Nov 11, 2026, against 6.1× a year earlier. Over the last 5 years it ranged from 1.9× to 12.0×, with a median of 3.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202612.0×+6.1
2025Dec 31, 20255.9×+2.6
2024Dec 31, 20243.3×+0.2
2023Dec 29, 20233.1×+0.3
2022Dec 30, 20222.7×−1.0
2021Dec 31, 20213.8×+0.9
2020Dec 31, 20202.9×+0.6
2019Dec 31, 20192.3×+0.7
2018Dec 31, 20181.6×–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?